Analysts Weigh on Biotech Giant Kite Pharma Inc (KITE) Following Q3 Earnings Release

Kite Pharma Inc (NASDAQ:KITE) released its Q3 earnings on November 12, beating analysts’ expectations. The company posted revenues of $5.1 million and a loss of ($0.63) per share, compared to analysts’ estimates of $4 million in revenue and a loss of ($0.73) per share. This quarter, the company announced that its pipeline drug, KTE-C19, will … Read more